Loading...

BBIO BRIDGEBIO PHARMA INC US FDA Inspections 8-K Filing

BRDG

BB

BRIDGEBIO PHARMA INC

(BBIO)

2026 8-K

Financial Results Report

Positive Phase 3 Results

Convertible Debt Offering

Financial Update

Positive Study Results

Q3 Financial Results

Positive Study Results

Financial Statements

Asset Acquisitions

Financial Statements

Management Changes

Financial Results

Financial Update

Q3 Financial Results

Gene Therapy Results

Joint Venture Formation

Financial Results

Appointment of President an...

Annual Meeting of Stockholders

Phase 2 Results Announcement

Financial Results

Underwriting Agreement for ...

License Agreement with Bayer

Financial Results

Funding Agreement for acora...

Presentation Update

Earnings Reports

Private Placement

Financial Results

Phase 3 Clinical Trial Results

Annual Meeting of Stockholders

Equity Distribution Agreement

Financial Results

Underwriting Agreement for ...

Positive Phase 2 results fo...

Financial Results and Manag...

External Links:

On March 30, 2026, BridgeBio Pharma, Inc. submitted a New Drug Application (NDA) to the FDA for BBP-418, aimed at treating individuals with LGMD2I/R9.

AI Assistant

BRIDGEBIO PHARMA INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.